Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Clinical Cancer Research
Clinical Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CCR Focus Archive
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Breast Cancer
      • Clinical Trials
      • Immunotherapy: Facts and Hopes
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Translational Cancer Mechanisms and Therapy

Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors

Goutam Chakraborty, Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa, Mohammad Atiq, Lina E. Jehane, Konrad H. Stopsack, Gwo-Shu Mary Lee, Wassim Abida, Michael J. Morris, Lorelei A. Mucci, Daniel Danila and Philip W. Kantoff
Goutam Chakraborty
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Goutam Chakraborty
  • For correspondence: kantoff@mskcc.org chakrabg@mskcc.org
Nabeela Khan Patail
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rahim Hirani
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Rahim Hirani
Subhiksha Nandakumar
2Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ying Z. Mazzu
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuki Yoshikawa
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Atiq
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mohammad Atiq
Lina E. Jehane
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Konrad H. Stopsack
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Konrad H. Stopsack
Gwo-Shu Mary Lee
3Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wassim Abida
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael J. Morris
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorelei A. Mucci
4Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Danila
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip W. Kantoff
1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: kantoff@mskcc.org chakrabg@mskcc.org
DOI: 10.1158/1078-0432.CCR-20-2483 Published March 2021
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Online Impact

Statistics from Altmetric.com

ARTICLE USAGE

ARTICLE USAGE: December 2020 to April 2021

AbstractFull-text HTMLPDF
Total3197111407

Cited By

Article Information

Volume 27, Issue 6, pp. 1792-1806

DOI 
https://doi.org/10.1158/1078-0432.CCR-20-2483
PubMed 
33334906

Published By 
American Association for Cancer Research
Print ISSN 
1078-0432
Online ISSN 
1557-3265
History 
  • Received June 29, 2020
  • Revision received November 4, 2020
  • Accepted December 14, 2020
  • Published first December 17, 2020.

Article Versions

  • Previous version (December 17, 2020 - 06:02).
  • Previous version (January 21, 2021 - 09:40).
  • You are viewing the most recent version of this article.
Copyright & Usage 
©2020 American Association for Cancer Research.

Author Information

  1. Goutam Chakraborty1,#,*,
  2. Nabeela Khan Patail1,#,
  3. Rahim Hirani1,
  4. Subhiksha Nandakumar2,
  5. Ying Z. Mazzu1,
  6. Yuki Yoshikawa1,
  7. Mohammad Atiq1,
  8. Lina E. Jehane1,
  9. Konrad H. Stopsack1,
  10. Gwo-Shu Mary Lee3,
  11. Wassim Abida1,
  12. Michael J. Morris1,
  13. Lorelei A. Mucci4,
  14. Daniel Danila1, and
  15. Philip W. Kantoff1,*
  1. 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
  2. 2Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
  3. 3Dana-Farber Cancer Institute, Boston, Massachusetts.
  4. 4Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  1. ↵*Corresponding Authors:
    Philip W. Kantoff, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 212-639-5851; Fax: 929-321-5023; E-mail: kantoff{at}mskcc.org; and Goutam Chakraborty, E-mail: chakrabg{at}mskcc.org
  1. ↵#G. Chakraborty and N. Khan Patail contributed equally as co-first authors of this article.

  • Current address for N. Khan Patail: Department of Medicine, Stony Brook University Hospital, Stony Brook, New York; and current address for M. Atiq, Division of Hematology-Oncology, Baylor College of Medicine, Houston, Texas.

View Full Text
PreviousNext
Back to top
Clinical Cancer Research: 27 (6)
March 2021
Volume 27, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Clinical Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
(Your Name) has forwarded a page to you from Clinical Cancer Research
(Your Name) thought you would be interested in this article in Clinical Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Goutam Chakraborty, Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa, Mohammad Atiq, Lina E. Jehane, Konrad H. Stopsack, Gwo-Shu Mary Lee, Wassim Abida, Michael J. Morris, Lorelei A. Mucci, Daniel Danila and Philip W. Kantoff
Clin Cancer Res March 15 2021 (27) (6) 1792-1806; DOI: 10.1158/1078-0432.CCR-20-2483

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Attenuation of SRC Kinase Activity Augments PARP Inhibitor–mediated Synthetic Lethality in BRCA2-altered Prostate Tumors
Goutam Chakraborty, Nabeela Khan Patail, Rahim Hirani, Subhiksha Nandakumar, Ying Z. Mazzu, Yuki Yoshikawa, Mohammad Atiq, Lina E. Jehane, Konrad H. Stopsack, Gwo-Shu Mary Lee, Wassim Abida, Michael J. Morris, Lorelei A. Mucci, Daniel Danila and Philip W. Kantoff
Clin Cancer Res March 15 2021 (27) (6) 1792-1806; DOI: 10.1158/1078-0432.CCR-20-2483
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Authors' Disclosures
    • Authors' Contributions
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Molecular Profiling of Metastatic Breast Cancer
  • Preclinical Evaluation of AMG 160 in mCRPC Models
  • Therapeutic Targeting NRG1 Fusion Cancers with Seribantumab
Show more Translational Cancer Mechanisms and Therapy
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • CCR Focus Archive
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Clinical Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Clinical Cancer Research
eISSN: 1557-3265
ISSN: 1078-0432

Advertisement